Pulmonary Arterial HypertensionPhase 1NCT05660863
A Multiple Dose Study to Investigate Safety, Tolerability and Pharmacokinetics of MN-08 Tablets
A Phase 1 study testing MN-08 24 mg/day and MN-08 60 mg/day in people with Pulmonary Arterial Hypertension, run by Guangzhou Magpie Pharmaceuticals Co., Ltd..
Trial summary
This trial is a single-center, Phase 1, placebo-controlled, double-blind, multiple-dose study in two ascending dose cohorts of healthy subjects. The primary objective of the trial is to assess the safety and tolerability of multiple doses of MN-08 tablet administered for 6.5 consecutive days in healthy subjects. Read more about this study
- Who is it for?
- Ages 18 to 45 yearsHealthy volunteers can take part
- Conditions the study is for
- Pulmonary Arterial Hypertension
- What is being tested?
- MN-08 24 mg/day and MN-08 60 mg/day
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 16 participants
- Where
- No sites listed yet
- Study dates
- 1 Sep 2027to 1 Jun 2028
- Phase
- Phase 1
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 45 years
- All sexes
- Healthy volunteers accepted
- Adult
Who may be able to join
- Subjects must meet all the following criteria to be included in the study:
- Male or female, non-smoker (no use of tobacco or nicotine products within 3 months prior to screening), ≥ 18 and ≤ 45 years of age, with body mass index (BMI) > 18.0 and < 30.0 kg/m2 , and body weight ≥ 50.0 kg for males and ≥ 45.0 kg for females.
- Healthy as defined by:
- the absence of clinically significant illness and surgery within 4 weeks prior to the first dosing. Subjects vomiting within 24 hours pre-dose will be carefully evaluated for upcoming illness/disease. Inclusion pre-dosing is at the discretion of the Investigator.
- the absence of a clinically significant history of neurological, endocrine, cardiovascular, respiratory, hematological, immunological, psychiatric, gastrointestinal, renal, hepatic, and metabolic disease.
- Female subjects must not be pregnant, breastfeeding, or at risk to become pregnant during study participation. Female subjects must have a negative serum pregnancy test at screening (within 72 hours of the first dose of study medication) if of childbearing potential, or be of non-childbearing potential. Non-childbearing potential is defined as:
Show all 15Show fewer
- post-menopausal female (absence of menses for 12 months prior to the first study drug administration, or having had a bilateral oophorectomy, or hysterectomy with bilateral oophorectomy at least 6 months prior to the first study drug administration); or
- surgically sterile female (hysterectomy or tubal ligation at least 6 months prior to drug administration).
- Female subjects of childbearing potential (childbearing potential defined as not post menopausal nor surgically sterile) must agree to use a reliable method of birth control (see below for details) or remain abstinent during the study, starting with the screening visit until at least 90 days after the last study drug administration.
- Male subjects who have not been vasectomized for at least 6 months, and who are sexually active with a female partner of childbearing potential must be willing to use one of the following acceptable contraceptive methods from the first study drug administration until at least 90 days after the last study drug administration:
- simultaneous use of a male condom and, for the female partner, hormonal contraceptives used since at least 4 weeks prior or intra-uterine contraceptive device placed since at least 4 weeks prior to study.
- simultaneous use of a male condom and, for the female partner, a diaphragm or cervical cap with intravaginally applied spermicide.
- Male subjects (including men who have had a vasectomy) with a pregnant partner must agree to use a condom from the first study drug administration until at least 90 days after the last study drug administration.
- Male subjects must be willing not to donate sperm until 90 days following the last study drug administration
- Capable of signing the informed consent form.
Who cannot join
- Subjects to whom any of the following applies will be excluded from the study:
- Any clinically significant abnormality at physical examination, clinically significant abnormal laboratory test results or positive test for hepatitis B, hepatitis C, or HIV found during medical screening.
- Subjects with any following clinical illness at screening, including but not limited to respiratory, circulatory, digestive, hematological, endocrine, immunological, dermatological, and ENT abnormalities.
- Subjects with digestive, liver, or kidney diseases which could affect the pharmacokinetics of drugs.
- Positive urine drug screen, alcohol breath test, or urine cotinine test at screening.
- History of allergic reactions to MN-08 or other related drugs, or to any excipient in the formulation.
Show all 24Show fewer
- Positive pregnancy test at screening.
- Clinically significant ECG abnormalities or vital sign abnormalities, including: systolic BP lower than 90 or over 139 mmHg, diastolic BP lower than 60 or over 89 mmHg, or HR less than 55 or over 100 bpm; orthostatic BP: decrease in systolic blood pressure of 20 mmHg or higher, decrease in diastolic blood pressure of 10 mmHg or higher, or increase in heart rate of 30 bpm or higher within 2 to 3 minutes after passing from a supine to a standing position at screening.
- History of significant alcohol abuse within 1 year prior to screening or regular use of alcohol within 6 months prior to the screening visit (more than 14 units of alcohol per week [1 unit = 150 mL of wine, 360 mL of beer, or 45 mL of 40% alcohol]).
- History of significant drug abuse within 1 year prior to screening, or use of soft drugs (such as marijuana) within 3 months prior to the screening visit, or hard drugs (such as cocaine, phencyclidine [PCP], crack, opioid derivatives including heroin, and amphetamine derivatives) within 1 year prior to screening.
- Subjects drinking excessive amounts of tea, coffee, or caffeinated beverages (more than 8 cups,1 cup = 250 mL) every day before the screening, or those who cannot agree to prohibit drinking tea, coffee, and/or products containing caffeine, grapefruit, or poppy 24 hours before dosing and during the study period.
- Smoking history of 5 cigarettes per day within 3 months before the study, or those who cannot stop smoking 24 h before dosing and during the study period.
- Have undergone major surgery 6 months before the study, or plan to have surgery during the study.
- Have been vaccinated within 3 months prior to the study.
- Participation in a clinical research study involving the administration of an investigational or marketed drug or device within 30 days prior to the first dosing, administration of a biological product in the context of a clinical research study within 90 days prior to the first dosing, or concomitant participation in an investigational study involving no drug or device administration.
- Use of medications for the time frames specified below, except for medications prescribed by the Investigator on a case-by-case basis because they have been judged unlikely to affect the pharmacokinetic profile of the study drug or subject safety (e.g., topical drug products without significant systemic absorption):
- Prescription medications within 14 days prior to the first dosing.
- Over-the-counter products and natural health products (including herbal remedies, homeopathic and traditional medicines, probiotics, food supplements such as vitamins, minerals, amino acids, essential fatty acids, and protein supplements used in sports) within 7 days prior to the first dosing, except for the occasional use of acetaminophen (up to 2 g daily).
- Depot injection or implantation of any drug within 3 months prior to the first dosing.
- Any drugs known to induce or inhibit hepatic drug metabolism (including St. John's Wort) within 30 days prior to the first dosing.
- Donation of plasma within 7 days prior to dosing. Donation or blood loss (excluding volume drawn at screening) of 50 mL to 499 mL of blood within 30 days, or more than 499 mL within 56 days prior to the first dosing.
- Any reason which, in the opinion of the Investigator, would prevent the subject from participating in the study.
- Breastfeeding subject.
- Any history of suicidal ideation or suicidal behavior (within 2 years prior to screening), as assessed by the Columbia-Suicide Severity Rating Scale (C-SSRS; baseline version).
Trial locations and contacts
No sites are listed yet. Contact the study team or a site near you to ask about taking part.
About this study
Official title: A Bridged Phase 1, Randomized, Double-blind, Placebo-controlled Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Multiple Dose of MN-08 in Healthy Subjects
This trial is a single-center, Phase 1, placebo-controlled, double-blind, multiple-dose study in two ascending dose cohorts of healthy subjects. The primary objective of the trial is to assess the safety and tolerability of multiple doses of MN-08 tablet administered for 6.5 consecutive days in healthy subjects.
- Conditions
- Pulmonary Arterial Hypertension
- Being tested
- MN-08 24 mg/day, MN-08 60 mg/day
- Medical subject headings
- Pulmonary Arterial Hypertension
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
MN-08 24 mg/dayDrug
Subjects in this cohort will receive 12 mg MN-08 tablets b.i.d. for a total daily dose of 24 mg or matching placebo for 6 consecutive days, and the last dose (12 mg) on the morning of Day 7.
MN-08 60 mg/dayDrug
Subjects in this cohort will receive 30 mg MN-08 tablets b.i.d. for a total daily dose of 60 mg or matching placebo tablets for 6 consecutive days, and the last dose (30 mg) on the morning of Day 7.
| Study group | Role | What they receive |
|---|---|---|
| cohort 1：MN-08 24 mg/day | Experimental | 2 x 6 mg MN-08 tablets for a total dose of 12 mg or 2 matching placebo tablets (given approximately every 12 hours) for 6.5 consecutive days, until the morning dose of Day 7. Receives: Drug: MN-08 24 mg/day |
| cohort 2：MN-08 60 mg/day | Experimental | 5 x 6 mg MN-08 tablets for a total dose of 30 mg or 5 matching placebo tablets (given approximately every 12 hours) for 6.5 consecutive days, until the morning dose of Day 7. Receives: Drug: MN-08 60 mg/day |
What is being measured
The primary outcome is the main question the study is designed to answer.
Incidence and severity of TEAEs and SAEs
Incidence and severity of treatment emergent adverse events (TEAEs) and Serious Adverse Events (SAEs) after multiple doses of MN-08 administered for 6.5 consecutive days in healthy subjects.
Measured: Through study completion, an average of 12 days
Incidence and severity of treatment-related adverse events
Incidence and severity of treatment-related adverse events determined by changes from screening (baseline) of findings from vital signs, ECG, and clinical laboratory parameters per the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 5.
Measured: Through study completion, an average of 12 days
Secondary outcomes (9)
Single dose peak plasma concentration (Cmax) for MN-08
Peak plasma concentration (Cmax) for MN-08 after single oral doses of MN-08 tablets.
Measured: Pre dose and up to 12 hours post dose after the morning dosing of Day 1.
Single dose area under the plasma concentration versus time curve (AUC) for MN-08
Area under the plasma concentration versus time curve (AUC) for MN-08 after single oral doses of MN-08 tablets.
Measured: Pre dose and up to 12 hours post dose after the morning dosing of Day 1.
Single dose time to peak plasma concentration (Tmax) for MN-08
Time to peak plasma concentration (Tmax) for MN-08 after single oral doses of MN-08 tablets.
Measured: Pre dose and up to 12 hours post dose after the morning dosing of Day 1.
Repeated dose peak plasma concentration (Cmax) for MN-08
Peak plasma concentration (Cmax) for MN-08 after multiple oral doses of MN-08 tablets.
Measured: Pre dose and up to 120 hours post dose after the morning dosing of Day 7.
Repeated dose steady-state plasma concentration (Css) for MN-08
Steady-state concentration (Css) for MN-08 after multiple oral doses of MN-08 tablets.
Measured: Pre dose and up to 120 hours post dose after the morning dosing of Day 7.
Repeated dose area under the plasma concentration versus time curve (AUC) for MN-08
Area under the plasma concentration versus time curve (AUC) for MN-08 after multiple oral doses of MN-08 tablets.
Measured: Pre dose and up to 120 hours post dose after the morning dosing of Day 7.
Repeated dose time to peak plasma concentration (Tmax) for MN-08
Time to peak plasma concentration (Tmax) for MN-08 after multiple oral doses of MN-08 tablets.
Measured: Pre dose and up to 120 hours post dose after the morning dosing of Day 7.
Repeated dose terminal elimination half-life (t1/2) for MN-08 in plasma
Terminal elimination half-life (t1/2) for MN-08 after multiple oral doses of MN-08 tablets.
Measured: Pre dose and up to 120 hours post dose after the morning dosing of Day 7.
Repeated dose ratio of accumulation (RA) for MN-08
Ratio of accumulation (RA) for MN-08 after multiple oral doses of MN-08 tablets.
Measured: Pre dose and up to 120 hours post dose after the morning dosing of Day 7.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted21 Dec 2022
- Study start1 Sep 2027 (estimated)
- Primary completion30 Mar 2028 (estimated)
- Study completion1 Jun 2028 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Pulmonary Arterial HypertensionStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 1
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind
- Who is masked
- Participant, Investigator
- Enrolment
- 16 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Guangzhou Magpie Pharmaceuticals Co., Ltd.
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05660863
- Sponsor's protocol ID
- 21607
- Status last verified
- Sep 2026
- First submitted
- 1 Dec 2022
- Last updated
- 14 Sep 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- Yes
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 14 Sep 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Bridged Phase 1, Randomized, Double-blind, Placebo-controlled Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Multiple Dose of MN-08 in Healthy Subjects
- ClinicalTrials.gov ID
- NCT05660863
- Acronym / sponsor ID
- 21607
- Conditions
- Pulmonary Arterial Hypertension
- Phase
- Phase 1
- Study type
- Interventional
- Recruitment status
- Not yet recruiting
- Enrolment
- 16 participants (estimated)
- Lead sponsor
- Guangzhou Magpie Pharmaceuticals Co., Ltd.Industry (pharma, biotech, devices)
- Study start
- 1 Sep 2027 (estimated)
- Primary completion
- 30 Mar 2028 (estimated)
- Study completion
- 1 Jun 2028 (estimated)
- First posted
- 21 Dec 2022 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This trial is a single-center, Phase 1, placebo-controlled, double-blind, multiple-dose study in two ascending dose cohorts of healthy subjects. The primary objective of the trial is to assess the safety and tolerability of multiple doses of MN-08 tablet administered for 6.5 consecutive days in healthy subjects.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind (participant, investigator)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| cohort 1：MN-08 24 mg/day | Experimental | Drug: MN-08 24 mg/day2 x 6 mg MN-08 tablets for a total dose of 12 mg or 2 matching placebo tablets (given approximately every 12 hours) for 6.5 consecutive days, until the morning dose of Day 7. |
| cohort 2：MN-08 60 mg/day | Experimental | Drug: MN-08 60 mg/day5 x 6 mg MN-08 tablets for a total dose of 30 mg or 5 matching placebo tablets (given approximately every 12 hours) for 6.5 consecutive days, until the morning dose of Day 7. |
Who may qualify
- Ages
- 18 to 45 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult
Key inclusion criteria (15 listed)
- Male or female, non-smoker (no use of tobacco or nicotine products within 3 months prior to screening), ≥ 18 and ≤ 45 years of age, with body mass index (BMI) > 18.0 and < 30.0 kg/m2 , and body weight ≥ 50.0 kg for males and ≥ 45.0 kg for females.
- Healthy as defined by:
- Female subjects must not be pregnant, breastfeeding, or at risk to become pregnant during study participation. Female subjects must have a negative serum pregnancy test at screening (within 72 hours of the first dose of study medication) if of childbearing potential, or be of non-childbearing potential. Non-childbearing potential is defined as:
- Female subjects of childbearing potential (childbearing potential defined as not post menopausal nor surgically sterile) must agree to use a reliable method of birth control (see below for details) or remain abstinent during the study, starting with the screening visit until at least 90 days after the last study drug administration.
- Male subjects who have not been vasectomized for at least 6 months, and who are sexually active with a female partner of childbearing potential must be willing to use one of the following acceptable contraceptive methods from the first study drug administration until at least 90 days after the last study drug administration:
Key exclusion criteria (24 listed)
- Any clinically significant abnormality at physical examination, clinically significant abnormal laboratory test results or positive test for hepatitis B, hepatitis C, or HIV found during medical screening.
- Subjects with any following clinical illness at screening, including but not limited to respiratory, circulatory, digestive, hematological, endocrine, immunological, dermatological, and ENT abnormalities.
- Subjects with digestive, liver, or kidney diseases which could affect the pharmacokinetics of drugs.
- Positive urine drug screen, alcohol breath test, or urine cotinine test at screening.
- History of allergic reactions to MN-08 or other related drugs, or to any excipient in the formulation.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| MN-08 24 mg/daySubjects in this cohort will receive 12 mg MN-08 tablets b.i.d. for a total daily dose of 24 mg or matching placebo for 6 consecutive days, and the last dose (12 mg) on the morning of Day 7. | Drug | cohort 1：MN-08 24 mg/day |
| MN-08 60 mg/daySubjects in this cohort will receive 30 mg MN-08 tablets b.i.d. for a total daily dose of 60 mg or matching placebo tablets for 6 consecutive days, and the last dose (30 mg) on the morning of Day 7. | Drug | cohort 2：MN-08 60 mg/day |
Primary outcome
Incidence and severity of TEAEs and SAEs
Time frame: Through study completion, an average of 12 days
Incidence and severity of treatment emergent adverse events (TEAEs) and Serious Adverse Events (SAEs) after multiple doses of MN-08 administered for 6.5 consecutive days in healthy subjects.
Incidence and severity of treatment-related adverse events
Time frame: Through study completion, an average of 12 days
Incidence and severity of treatment-related adverse events determined by changes from screening (baseline) of findings from vital signs, ECG, and clinical laboratory parameters per the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 5.
9 secondary outcomes
Single dose peak plasma concentration (Cmax) for MN-08
Time frame: Pre dose and up to 12 hours post dose after the morning dosing of Day 1.
Single dose area under the plasma concentration versus time curve (AUC) for MN-08
Time frame: Pre dose and up to 12 hours post dose after the morning dosing of Day 1.
Single dose time to peak plasma concentration (Tmax) for MN-08
Time frame: Pre dose and up to 12 hours post dose after the morning dosing of Day 1.
Repeated dose peak plasma concentration (Cmax) for MN-08
Time frame: Pre dose and up to 120 hours post dose after the morning dosing of Day 7.
Repeated dose steady-state plasma concentration (Css) for MN-08
Time frame: Pre dose and up to 120 hours post dose after the morning dosing of Day 7.
Repeated dose area under the plasma concentration versus time curve (AUC) for MN-08
Time frame: Pre dose and up to 120 hours post dose after the morning dosing of Day 7.
Repeated dose time to peak plasma concentration (Tmax) for MN-08
Time frame: Pre dose and up to 120 hours post dose after the morning dosing of Day 7.
Repeated dose terminal elimination half-life (t1/2) for MN-08 in plasma
Time frame: Pre dose and up to 120 hours post dose after the morning dosing of Day 7.
Repeated dose ratio of accumulation (RA) for MN-08
Time frame: Pre dose and up to 120 hours post dose after the morning dosing of Day 7.
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 14 Sep 2026.
Related trials for Pulmonary Arterial Hypertension
RecruitingPhase 2/3
The Effect of Additive On-Demand Sildenafil vs. Dextrose Candy on Maximum Exercise Capacity in Pulmonary Arterial Hypertension
Pulmonary Arterial Hypertension (PAH) (WHO Group 1 PH)
Not yet recruiting
Home-based Inspiratory Muscle Training in Pulmonary Hypertension
Pulmonary Arterial Hypertension, Chronic Thromboembolic Pulmonary Hypertension
RecruitingPhase 4
A Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (PAH) in India (MK-7962-037)
Pulmonary Arterial Hypertension
RecruitingObservational study
Early Detection of CTEPH in Patients After APE
Chronic Pulmonary Thromboembolism
Recruiting
The Effect of Levosimendan on Pulmonary Artery Pressure and Right Ventricular Function in the Perioperative Period in Patients With CTEPH After Pulmonary Thromboendarterectomy
LEVOSIMENDAN, PULMONARY THROMBOENDARTERECTOMY
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Questions about this trial
What is this clinical trial studying?
A Phase 1 study testing MN-08 24 mg/day and MN-08 60 mg/day in people with Pulmonary Arterial Hypertension, run by Guangzhou Magpie Pharmaceuticals Co., Ltd..
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 15 inclusion and 24 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 14 Sep 2026. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Roy Feng, Doctor (412-509-7201, fengrentian@hotmail.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Incidence and severity of TEAEs and SAEs (time frame: Through study completion, an average of 12 days). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 14 Sep 2026.